On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for the Section 503A Bulks List, the roster that determines which unapproved substances licensed pharmacies may compound for individual patients. The votes overrode the unanimous position of the agency's career scientists, who had advised against including any of the seven peptides under review. The seventh compound, emideltide, was rejected 6 to 7 and became the meeting's only failure. The American Journal of Managed Care reported that the outcome was atypical: a PCAC panel had rarely, if ever, voted against FDA staff's written recommendation.
On the first day at FDA's White Oak campus in Silver Spring, Maryland, BPC-157, KPV, and TB-500 each passed 8 to 6 with one abstention, while MOTS-c cleared by 7 to 5 with two abstentions. Semax passed 8 to 5 and Epitalon 7 to 4 on the second day. None of the six peptides has been placed on the 503A Bulks List, none holds FDA drug approval, and no pharmacy may legally compound them today. The committee's recommendation is advisory. The FDA must still decide whether to accept it and, if so, proceed through notice-and-comment rulemaking—a proposed rule, a public comment period, and a final rule—before compounding could begin.
A Narrow Vote Against the Agency's Own Science
FDA reviewers prepared fourteen separate recommendations covering both chemical forms of each peptide and advised against every one. Their briefing materials cited short, underpowered studies insufficient to establish safety or effectiveness across proposed indications spanning ulcerative colitis, wound healing, obesity, osteoporosis, and opioid withdrawal. For BPC-157, the most widely marketed of the six, scientists identified a single human trial—a small 2005 study published only as a conference abstract—and no human safety data for the injectable, oral, or nasal forms consumers currently purchase. TB-500, KPV, and MOTS-c carried no human studies of any kind, in any dose, for any purpose. NPR reported that agency scientists also flagged variability in the chemical makeup of different production batches and the possibility that the compounds could provoke harmful immune responses.
Eight of the committee's voting members were appointed this spring, roughly four to ten weeks before the meeting. For the BPC-157, KPV, and TB-500 votes, all eight new appointees voted yes. NBC News documented that the Associated Press had reported financial ties to peptide businesses among several of those new members. Dr. Brian Lee, an associate professor of medicine at the Keck School of Medicine of USC, voted no and warned that the public could interpret the panel's recommendation as an endorsement of the products' safety. "For effectiveness, we know that 30 percent of patients on placebo will have a self-reported response or even objective response," Lee said during the meeting.
What a 503A Listing Would and Would Not Change
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacist may compound a drug without full approval only if the substance is a component of an already-approved drug or appears on the 503A Bulks List. None of the six peptides meets either criterion today. The PCAC vote represents the only procedural opening through which they could reach that list without a full New Drug Application. For readers tracking the broader legal status of these compounds, our guide on whether peptides are legal outlines the current enforcement landscape.
If the FDA ultimately accepts the recommendation and finalizes a rule, licensed 503A compounding pharmacies could prepare the peptides for patients holding a valid prescription, subject to sterility and quality-control standards. Patients would likely pay out of pocket, because compounded drugs generally fall outside standard pharmacy-benefit coverage. The substances would not become over-the-counter supplements, and the designation would not constitute a finding of safety or efficacy. A full accounting of which compounds have actually cleared the approval bar is available in our reference on FDA approved peptides.
Panel members who voted yes framed their support as a harm-reduction measure aimed at steering consumers away from unregulated online vendors. Dr. Haleem Mohammed, a committee member, said during the Thursday session: "When I look at something like saying no to this and pushing it to the gray market, am I doing greater harm? That's what I lose sleep at night over." The reference point was the existing trade in unmarked vials sold as research chemicals through overseas suppliers, a market our reporting on grey market peptides has tracked across U.S. and Pacific supply chains.
The Rulemaking Gap and Political Pressure
HHS Secretary Robert F. Kennedy Jr., who oversees the FDA, has publicly stated that he uses peptides and has supported broader access. In February 2026, Kennedy announced that approximately fourteen peptides on the FDA's Category 2 restricted compounding list would be moved toward Category 1 eligibility, a policy shift that preceded the PCAC meeting by five months. Food and drug law attorneys at Hyman, Phelps & McNamara have noted that Kennedy could also direct the FDA to permit compounding immediately, bypassing the rulemaking timeline, though no such directive has been issued as of this writing.
The FDA has not announced whether it will accept the committee's recommendations. The agency is under no statutory obligation to do so. If it proceeds, the notice-and-comment process would invite public submissions before a final rule could take effect. Until that process concludes, the six peptides remain in the same regulatory position they occupied before the July vote: unapproved, restricted, and unavailable through legal pharmacy channels in the United States. Clinics or telehealth platforms currently advertising these compounds as "FDA cleared" or "now legal" are making claims unsupported by any completed agency action. The next concrete step belongs to FDA leadership, which must decide whether to convert a narrow advisory margin into binding regulation over the documented objections of its own scientific staff.
